Literature DB >> 10630642

BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene.

J N Snouwaert1, L C Gowen, A M Latour, A R Mohn, A Xiao, L DiBiase, B H Koller.   

Abstract

BRCA1 is a nuclear phosphoprotein that has been classified as a tumor suppressor based on the fact that women carrying a mutated copy of the BRCA1 gene are at increased risk of developing breast and ovarian cancer. The association of BRCA1 with RAD51 has led to the hypothesis that BRCA1 is involved in DNA repair. We describe here the generation and analysis of murine embryonic stem (ES) cell lines in which both copies of the murine homologue of the human BRCA1 gene have been disrupted by gene targeting. We show that exogenous DNA introduced into these BRCA1 deficient cells by electroporation is randomly integrated into the genome at a significantly higher rate than in wild type ES cells. In contrast, integration of exogenous DNA by homologous recombination occurs in BRCA1 deficient cells at a significantly lower rate than in wild type controls. When BRCA1 expression is re-established at 5-10% of normal levels by introduction of a Brca1 transgene into BRCA1 deficient ES cells, the frequency of random integration is reduced to wild type levels, although the frequency of homologous recombination is not significantly improved. These results suggest that BRCA1 plays a role in determining the response of cells to double stranded DNA breaks.

Entities:  

Mesh:

Year:  1999        PMID: 10630642     DOI: 10.1038/sj.onc.1203334

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  63 in total

Review 1.  Manipulating the mammalian genome by homologous recombination.

Authors:  K M Vasquez; K Marburger; Z Intody; J H Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

2.  BRCA1 at a branch point.

Authors:  J D Parvin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

3.  Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.

Authors:  Caroline C Clark; Jeffrey N Weitzel; Timothy R O'Connor
Journal:  Mol Cancer Ther       Date:  2012-07-09       Impact factor: 6.261

Review 4.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

Review 5.  Role of 53BP1 in the regulation of DNA double-strand break repair pathway choice.

Authors:  Arun Gupta; Clayton R Hunt; Sharmistha Chakraborty; Raj K Pandita; John Yordy; Deepti B Ramnarain; Nobuo Horikoshi; Tej K Pandita
Journal:  Radiat Res       Date:  2013-12-09       Impact factor: 2.841

Review 6.  BRCA1 Mutation: A Predictive Marker for Radiation Therapy?

Authors:  Charlene Kan; Junran Zhang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-10-01       Impact factor: 7.038

7.  Genetic steps of mammalian homologous repair with distinct mutagenic consequences.

Authors:  Jeremy M Stark; Andrew J Pierce; Jin Oh; Albert Pastink; Maria Jasin
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

Review 8.  53BP1: pro choice in DNA repair.

Authors:  Michal Zimmermann; Titia de Lange
Journal:  Trends Cell Biol       Date:  2013-10-04       Impact factor: 20.808

9.  Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability.

Authors:  Ellen E McCarthy; Julide T Celebi; Richard Baer; Thomas Ludwig
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

Review 10.  FANCJ helicase operates in the Fanconi Anemia DNA repair pathway and the response to replicational stress.

Authors:  Yuliang Wu; Robert M Brosh
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.